EGFR Inhibitors

Aug 03, 2026

Summary PROTACs represent a new modality that eliminates target proteins by leveraging the cell’s ubiquitin-proteasome system. Vepdegestrant (VEPPANU) became the first FDA-approved PROTAC therapy in May 2026 for the treatment of ER+/HER2- ESR1-mutated breast cancer, representing a significant milestone for t...

Jul 21, 2025

Eight years after its founding, partly backed by AstraZeneca, Dizal Pharmaceuticals has secured its first FDA approval, receiving accelerated clearance for ZEGFROVY (sunvozertinib)—now the only FDA-approved oral therapy for a rare subset of non-small cell lung cancer (NSCLC). The treatment is indicated for U.S. ...

Mar 29, 2024

In the realm of cancer treatment, the development of targeted therapies has been nothing short of revolutionary. Among these advancements, EGFR inhibitors have emerged as a powerful weapon in the fight against certain types of cancer. EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of c...